Get started
Author

Hugo Veyssière

Observed names: H. Veyssiere, HUGO VEYSSIÈRE, Hugo Veyssiere, Veyssiere, Hugo
Institution: Centre Jean Perrin
Observed institutions: Centre National de la Recherche Scientifique, Inserm, Université Clermont Auvergne, Centre Jean Perrin, Centre Hospitalier Universitaire de Clermont-Ferrand, Institut Génétique, Reproduction et Développement, Imagerie Moléculaire et Stratégies Théranostiques, Université de Clermont I
ORCID: 0000-0003-2202-7362
Observed ORCID: 0000-0003-2202-7362
OpenAlex ID: A5038033254
Circulating proteins as predictive and prognostic biomarkers in breast cancer
2022 · Hugo Veyssière, Yannick Bidet, et al. · Clinical Proteomics · 59
PDF
Artificial intelligence solution to classify pulmonary nodules on CT
2020 · D. Blanc, V. Racine, et al. · Diagnostic and Interventional Imaging · 45
PDF
RFID trial: localization of non-palpable breast lesions using radiofrequency identification tags or wire
2023 · Hugo Veyssiere, Margot Dressaire, et al. · BMC Cancer · 10
PDF
Multiple functions of the scaffold protein Discs large 5 in the control of growth, cell polarity and cell adhesion in Drosophila melanogaster
2020 · Parvathy Venugopal, Hugo Veyssière, et al. · BMC Developmental Biology · 9
PDF
INSTIGO Trial: Evaluation of a Plasma Protein Profile as a Predictive Biomarker for Metastatic Relapse of Triple Negative Breast Cancer
2021 · Hugo Veyssière, Sejdi Lusho, et al. · Frontiers in Oncology · 7
PDF
Pembrolizumab as a novel therapeutic option for patients with refractory thymic epithelial tumor: A case report
2021 · Jonathan Wong-Chong, Maureen Bernadach, et al. · World Journal of Clinical Cases · 6
PERCEPTION Trial protocol
2020 · Sejdi Lusho, Xavier Durando, et al. · Medicine · 6
Nestin as a Prognostic Biomarker in High-grade Epithelial Ovarian Cancer Treated by Neoadjuvant Chemotherapy
2022 · HUGO VEYSSIÈRE, GHASSAN ALDARAZI, et al. · Anticancer Research · 4
XENOBREAST Trial: A prospective study of xenografts establishment from surgical specimens of patients with triple negative or luminal b breast cancer
2020 · Hugo Veyssière, Judith Passildas, et al. · F1000Research · 3
Durable Response to Crizotinib in a Patient with Pulmonary Adenocarcinoma Harboring MET Intron 14 Mutation: A Case Report
2021 · Brice Leyrat, Xavier Durando, et al. · OncoTargets and Therapy · 1
PDF
Identification of serum proteins associated with response of triple-negative breast cancer to neoadjuvant chemotherapy: preliminary results from the INSTIGO trial
2025 · Celeste Pinard, Angeline Ginzac, et al. · Clinical Proteomics
PDF
Additional file 1 of RFID trial: localization of non-palpable breast lesions using radiofrequency identification tags or wire
2023 · Veyssiere, Hugo, Dressaire, Margot, et al. · Figshare
Optimisation de la prise en charge des patientes atteintes d’un cancer du sein. De la biologie à la clinique
2022 · Hugo Veyssiere · theses.fr (ABES)
XENOBREAST Trial: A prospective study of xenografts establishment from surgical specimens of patients with triple negative or luminal b breast cancer
2021 · Hugo Veyssière, Judith Passildas, et al. · F1000Research
Works count: 15
Citation count: 150
H-index: 6
I10-index: 3
Year
Topic
Type